Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

全面介紹

Na minha lista:
書目詳細資料
發表在:Haematologica
Main Authors: Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
格式: Artigo
語言:Inglês
出版: Ferrata Storti Foundation 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://ncbi.nlm.nih.gov/pubmed/30545923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201152
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍